Skip to main content
Premium Trial:

Request an Annual Quote

Wales to Routinely Screen Cancer Patients With Yourgene Elucigene Test

NEW YORK -- UK-based molecular diagnostics firm Yourgene Health said on Monday its Elucigene DPYD test is now being offered to all patients undergoing chemotherapy in Wales.

Wales implemented a screening program to routinely test all patients undergoing chemotherapy with the Elucigene DPYD test. The screening identifies patients with ihydropyrimidine dehydrogenase (DPD) deficiency, which can lead to severe side effects in patients being treated with chemotherapeutic drug 5-fluorouracil.

The drug is commonly used to treat colon, esophageal, stomach, pancreatic, breast and cervical cancers. 5-FU is metabolized by the DPD enzyme, which is encoded by the DPYD gene.

Wales began the pilot program earlier this year and has already taken 400 samples with 6 percent of patients coming back positive for DPD. Now, all health boards across Wales are offering the screening with Yourgene the only provider of the test.

Yourgene will provide tests to screen for approximately 200 patients each month for the next year, it said.

The Scan

Just Breathing

A new analysis suggests that most Mycobacterium tuberculosis is spread by aerosols from breathing, rather than by coughing, the New York Times reports.

Just Like This One

NPR reports that the World Health Organization has hired a South African biotech company to recreate mRNA vaccine for SARS-CoV-2 that is similar to the one developed by Moderna.

Slow Start

The Wall Street Journal reports that Biogen's Alzheimer's disease treatment had revenues for July through September that totaled $300,000.

Genome Research Papers on Cancer Chromatin, Splicing in the Thymus, Circular RNAs in Cancer

In Genome Research this week: analysis of bivalent chromatin sites, RBFOX splicing factors' role in thymic epithelial cells, and more.